The importance of the HER2 receptor in signalling and survival in HER2-positive breast cancer cell lines was supported by the strong antiproliferative effect of ibrutinib and zanubrutinib at submicromolar concentrations in these cell lines compared to cells with low expression of HER2, which were insensitive to BTK inhibitors. The gene discussed is ERBB2; the disease is breast carcinoma.